EU Panel Recommends Orphan Drug Status for Ibudilast for ALS Treatment
The European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending that ibudilast (MN-166) receives orphan medicinal product (orphan drug designation) for the treatment of amyotrophic lateral sclerosis (ALS). MediciNova is currently focusing on the development of ibudilast for neurological disorders…